Table 1 Patients’ characteristics
N = 247 | % | |
|---|---|---|
Age (years) | ||
Median (range) | 30 (17–67) | |
Histology | ||
Pure seminoma | 50 | 20.2 |
Non-seminoma or mixed GCT | 197 | 79.8 |
Primary tumor | ||
Gonadal | 238 | 96.4 |
Primary retroperitoneal | 7 | 2.8 |
Primary mediastinal | 2 | 0.9 |
IGCCCG risk group | ||
Good risk | 184 | 74.5 |
Intermediate risk | 29 | 11.7 |
Poor risk | 34 | 13.8 |
Sites of metastases | ||
Retroperitoneum | 175 | 70.9 |
Mediastinum | 32 | 13.0 |
Lungs | 60 | 24.3 |
Liver | 18 | 7.3 |
Other | 34 | 13.8 |
Non-pulmonary visceral metastases | 22 | 8.9 |
No. of metastatic sites | ||
0 | 63 | 25.5 |
1–2 | 141 | 57.1 |
> 3 | 43 | 17.4 |
Mean (range) of pre-treatment markers | ||
AFP mIU/ml | 1274 (0–60,570) | |
β-HCG IU/ml | 10,412 (0–423,338) | |
LDH (mkat/l) | 12 (2–89) | |